{"id":6130,"date":"2024-09-03T10:55:17","date_gmt":"2024-09-03T10:55:17","guid":{"rendered":"https:\/\/demopublication.edutechy.xyz\/?p=6130"},"modified":"2025-04-26T09:54:04","modified_gmt":"2025-04-26T09:54:04","slug":"chapter-16-ich-guidelines-for-pharmacovigilance-ii","status":"publish","type":"post","link":"https:\/\/sproutpublication.com\/index.php\/2024\/09\/03\/chapter-16-ich-guidelines-for-pharmacovigilance-ii\/","title":{"rendered":"Chapter 16: ICH Guidelines for Pharmacovigilance-II"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-right:20px;--awb-padding-left:20px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-border-color:var(--awb-color3);--awb-border-style:solid;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\" style=\"--awb-content-alignment:justify;--awb-font-size:16px;\"><p><strong>Author: <\/strong>Mr. Ashutosh Jain<br \/>\n<strong>Volume: <\/strong>01<br \/>\n<strong>First Online: <\/strong>31 August 2024<br \/>\n<strong>Pages: <\/strong> 239-259<br \/>\n<strong>DOI:<\/p>\n<\/div><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"--awb-text-color:var(--awb-color8);--awb-font-size:20px;\"><h2 class=\"fusion-title-heading title-heading-left\" style=\"font-family:&quot;Roboto&quot;;font-style:normal;font-weight:700;margin:0;font-size:1em;\">Abstract<\/h2><\/div><div class=\"fusion-separator\" style=\"align-self: flex-start;margin-right:auto;margin-bottom:20px;width:100%;max-width:8%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"--awb-height:20px;--awb-amount:20px;--awb-sep-color:var(--awb-custom_color_1);border-color:var(--awb-custom_color_1);border-top-width:3px;\"><\/div><\/div><div class=\"fusion-text fusion-text-2\" style=\"--awb-content-alignment:justify;--awb-font-size:16px;--awb-text-font-family:&quot;Roboto&quot;;--awb-text-font-style:normal;--awb-text-font-weight:400;\"><p>The second part of the ICH guidelines for pharmacovigilance focuses on advanced aspects of drug safety monitoring, including signal detection, risk management, and the integration of real-world evidence. Key guidelines such as ICH E2E on pharmacovigilance planning emphasize proactive risk management through the development of Risk Management Plans (RMPs) for new drugs. ICH E2D and E2F provide frameworks for post-approval safety data management and Development Safety Update Reports (DSURs), ensuring continuous safety evaluation throughout a drug\u2019s lifecycle. These guidelines are crucial for maintaining a drug\u2019s benefit-risk balance and for the harmonization of pharmacovigilance practices globally. By adopting these guidelines, regulatory authorities and pharmaceutical companies can better manage drug safety, protect public health, and respond effectively to emerging safety concerns.<\/p>\n<p><strong>Keywords:<\/strong> ICH Guidelines, Pharmacovigilance, Drug Safety Monitoring, Signal Detection, Risk Management, Real-World Evidence, ICH E2E<\/p>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[144],"tags":[],"class_list":["post-6130","post","type-post","status-publish","format-standard","hentry","category-pharmacovigilance"],"_links":{"self":[{"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/posts\/6130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/comments?post=6130"}],"version-history":[{"count":4,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/posts\/6130\/revisions"}],"predecessor-version":[{"id":7332,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/posts\/6130\/revisions\/7332"}],"wp:attachment":[{"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/media?parent=6130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/categories?post=6130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sproutpublication.com\/index.php\/wp-json\/wp\/v2\/tags?post=6130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}